Volume : 08, Issue : 12, December – 2021

Title:

10.INAPPROPRIATE USE OF PROTON PUMP INHIBITORS, TIME TO REASSESS INDICATIONS

Authors :

Ghulam Fareed, Hasham Nawaz, Wajid Iqbal, SM. Nabeel Noor, Shahab Abid

Abstract :

Introduction: Proton pump inhibitors are one of the most commonly prescribed and most commonly used medications worldwide, both in primary, secondary, and tertiary care settings. In the majority of cases, they are used inappropriately without any clear-cut indication hence leading to lots of unnecessary health related costs both nationally and internationally. Also, misuse is associated with potential complications. Due to the current dearth of available data regarding use and misuse of PPIs in Pakistan, there is an urgent need to assess appropriateness of PPI use both in primary and tertiary care settings to avoid the potentially devastating financial and public health concerns. Materials and Methods: It is a retrospective observational study conducted in department of medicine, Aga khan university hospital karachi, over a period of one year. There was total 13,346 patients admitted in the hospital during the specified period under care of Medicine and allied 6950/13346 (52%), OBGYN 379/13346 (3%) and General surgery and allied 6017/13346 (45%). Estimated sample size was 980 patients and similar percentages of patients were taken from above groups via simple random sampling
Results: Out of 797 patients, 367 (46%) had an FDA-approved indication for PPIs use, 213 (26.7%) had alternate indications as recommended by clinical practice guidelines whereas remaining 217 patients (27.2%) were treated with PPI without any approved indications Conclusion: The results of this study showed that every fourth patient in hospital is getting PPIs without fulfilling indications as per established evidence based clinical practice guidelines.
Key Words: Proton pump inhibitor, PPIS misuse, Financial and health concerns, Approved indications, Inappropriate indications, potential complications

Cite This Article:

Please cite this article in press Wajid Iqbal et al, Inappropriate Use Of Proton Pump Inhibitors, Time To Reassess Indications., Indo Am. J. P. Sci, 2021; 08(12)

Number of Downloads : 10

References:

1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. British Medical Journal Publishing Group; 2008.
2. Luo H, Fan Q, Xiao S, Chen K. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital. BMC Health Services Research. 2018;18(1):537.
3. Boucherie Q, Rouby F, Frankel D, Roll P, Micallef J. Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapies. 2018;73(5):385-8.
4. Aznar‐Lou I, Reilev M, Lødrup AB, Rubio‐Valera M, Haastrup PF, Pottegård A. Use of proton pump inhibitors among Danish children: A 16‐year register‐based nationwide study. Basic & clinical pharmacology & toxicology. 2019;124(6):704-10.
5. Venkataraman R, Rashid M, Shrestha H. Inappropriate Medication Use and Cost Comparison Analysis of Proton Pump Inhibitors: Evidence from an Indian Tertiary Care Facility. Current drug safety. 2020;15(2):147-55.
6. Nallapeta N, Reynolds JL, Bakhai S. Deprescribing Proton Pump Inhibitors in an Academic, Primary Care Clinic: Quality Improvement Project. Journal of clinical gastroenterology. 2020;54(10):864-70.
7. Boster J, Lowry LE, Bezzant ML, Kuiper B, Surry L. Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic. Cureus. 2020;12(1).
8. Pasina L, Novella A, Elli C, Nobili A, Ianes A. Overuse of proton pump inhibitors in nursing homes: An Italian multicenter observational study. Pharmacoepidemiology and Drug Safety. 2020;29(4):461-6.
9. Shafi S, Soomro R, Abbas SZ. Proton pump inhibitors–overprescribed in a rural community. Pak J Med Sci. 2011;27(2):300-2.
10. Donnellan C, Preston C, Moayyedi P, Sharma N. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews. 2004(4).
11. Piper DW. A comparative overview of the adverse effects of antiulcer drugs. Drug safety. 1995;12(2):120-38.
12. Dial S, Delaney J, Barkun AN, Suissa S. Use of gastric acid–suppressive agents and the risk of community-acquired Clostridium difficile–associated disease. Jama. 2005;294(23):2989-95.
13. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. Jama. 2006;296(24):2947-53.
14. Leonard M. Esomeprazole (Nexium™): A New Proton Pump Inhibitor 2001 [19/11/2020]. Available from: https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/julyaugust2001/eso_table1.htm.
15. Villamañán E, Ruano M, Lara C, Suárez-de-Parga JM, Armada E, Álvarez-Sala R, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Revista Española de Enfermedades Digestivas. 2015;107(11):652-8.
16. Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. European Journal of Clinical Pharmacology. 2020;76(3):449-57.
17. Souaid CK, Maalouf RG, Hallit S, Akiki B, Dagher E. Relevance of proton pump inhibitors prescriptions in a tertiary care hospital in Lebanon. Arab Journal of Gastroenterology. 2020;21(3):194-8.
18. Lenoir C, El Biali M, Luthy C, Grosgurin O, Desmeules JA, Rollason V. Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more? International Journal of Clinical Pharmacy. 2019;41(6):1634-41.
19. Ying J, Li L-C, Wu C-Y, Yu Z-W, Kan L-D. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva. 2019;111.
20. Shi Y-C, Cai S-T, Tian Y-P, Zhao H-J, Zhang Y-B, Chen J, et al. Effects of proton pump inhibitors on the gastrointestinal microbiota in gastroesophageal reflux disease. Genomics, proteomics & bioinformatics. 2019;17(1):52-63.
21. Gommers LMM, Ederveen THA, van der Wijst J, Overmars-Bos C, Kortman GAM, Boekhorst J, et al. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia. FASEB J. 2019;33(10):11235-46.
22. Ma Y-J, Cao Z-X, Li Y, Feng S-Y. Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis. World Journal of Gastroenterology. 2019;25(21):2675.
23. Scarpignato C, Tolone S. Addressing long-term PPI safety. Digestive and Liver Disease. 2020;52(8):853-6.
24. Luo H, Fan Q, Bian T, Li X, Chen K, Zhang Q, et al. Awareness, attitude and behavior regarding proton pump inhibitor among medical staff in the Southwest of China. BMC health services research. 2019;19(1):880.
25. Verma N, Tayal V, Roy V. Proton Pump Inhibitors: Prescribing Practices, Appropriateness of Use, and Cost Incurred in a Tertiary Care, Public, Teaching Hospital in New Delhi, India. MAMC Journal of Medical Sciences. 2019;5(3):113.